At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
URO-902 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence
In Brief
A Phase 2 clinical trial evaluating URO-902 and Placebo for Overactive Bladder With Urge Urinary Incontinence. Completed, enrolled 80 participants across 20 sites.
Detailed Summary
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder (OAB) and urge urinary incontinence (UUI) up to 48 weeks post-dose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionNov 2021
Study CompletionJul 2022
TodayJul 2026
First PostedDec 26, 2019
Enrollment StartDec 16, 2019
Primary CompletionNov 18, 2021
Study CompletionJul 20, 2022
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 6.5 years ago
Interventions
URO-902drug
intradetrusor injection
Placebodrug
intradetrusor injection